Understanding how melanoma evolves resistance to targeted therapies
Official title: Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance
Funded at University of California Los Angeles · NIH-11045705 · Data updated 2026-11-12
This study is looking at why some melanoma patients don’t respond well to certain treatments and aims to find better options for both those with the BRAFV600 mutation and those without, so that everyone can get more effective care based on their specific type of melanoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $582,364 |
| NIH project number | 5R01CA282198-02 |
| Project ID | NIH-11045705 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with melanoma, particularly those with BRAFV600 mutant or wildtype subtypes.
✕Less likely to help
Patients with melanoma who have already exhausted all treatment options or those with non-melanoma skin cancers may not benefit from this research.
What this research studies
This research investigates the mechanisms behind resistance to MAPK inhibitors in melanoma, particularly focusing on both BRAFV600 mutant and wildtype melanoma patients. By creating a comprehensive bank of patient-derived xenografts, the study aims to explore how different melanoma subtypes develop resistance to treatment. The approach includes analyzing the proteogenomic profiles of these subtypes to identify potential combinatorial therapies that could enhance treatment efficacy. Patients may benefit from insights that could lead to more effective treatment options tailored to their specific melanoma subtype.
Why it matters
Potential benefit: If successful, this research could lead to new combination therapies that effectively prevent or reverse resistance to melanoma treatments.
How similar studies have gone: Previous research has shown promise in understanding resistance mechanisms in melanoma, but this approach aims to provide a more comprehensive and novel perspective.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Lo, Roger S — University of California Los Angeles
- Study coordinator: Lo, Roger S
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.